CG Oncology, Inc. Overview
Pro stress-test →CG Oncology is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company is positioned as a leading contender in high-risk BCG-unresponsive NMIBC with its oncolytic adenovirus, cretostimogene grenadenorepvec.
Strategic Profile
Pro stress-test →As of February 2026, CG Oncology has approximately $903.0 million in cash to fund operations into 2029. The company announced an expedited timeline for PIVOT-006 nearly a year ahead of schedule, which is the first Phase 3 randomized trial in intermediate-risk NMIBC encompassing the broadest range of patient types per AUA/SUO Guidelines. CG Oncology maintains a "Strong Buy" rating driven by significant pipeline progress and multiple upcoming catalysts in 2026.
Competitive Landscape
Pro stress-test →CG Oncology positions its oncolytic adenovirus cretostimogene as a leading competitor in the high-risk BCG-unresponsive NMIBC space, with efficacy and safety data rivaling Johnson & Johnson offerings. The company targets a large unmet need in bladder cancer where standard BCG therapy fails or cannot be tolerated.
Industry Context
CG Oncology, Inc. operates in Biotechnology / Oncology.
Key facts
Founded: 2010 · Headquarters: Irvine, California · Employees: 113 · Revenue: $0